Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
A stepwise approach is generally recommended, starting with conservative measures before progressing to pharmacological interventions
GSK is paying $500 million upfront to get the ball rolling on the alliance, claiming rights to the first programme, a PDE3/4 inhibitor codenamed HRS-9821 in clinical development for the treatment of chronic obstructive pulmonary disease (COPD), outside China and some of its territories
Environ Toxicol Pharmacol 25(1):3942
That is much higher than the roughly 1% yield you'd collect from an S&P 500 index (SNPINDEX: ^GSPC) fund
If youre just a few days late, take it when you remember
US$ 23.65
US$ 27.29
US$ 22.99
US$ 26.95
US$ 26.39
US$ 24.40
US$ 23.48
US$ 23.50
US$ 23.61
